Thermogenesis Holdings, Inc. (THMO): Price and Financial Metrics


Thermogenesis Holdings, Inc. (THMO): $0.83

-0.02 (-1.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

THMO POWR Grades


  • THMO scores best on the Growth dimension, with a Growth rank ahead of 94.22% of US stocks.
  • THMO's strongest trending metric is Growth; it's been moving up over the last 42 days.
  • THMO ranks lowest in Stability; there it ranks in the 9th percentile.

THMO Stock Summary

  • ThermoGenesis Holdings Inc's market capitalization of $10,065,457 is ahead of merely 0.48% of US-listed equities.
  • The volatility of ThermoGenesis Holdings Inc's share price is greater than that of 91.53% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for THMO comes in at -103.39% -- higher than that of only 4.08% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ThermoGenesis Holdings Inc, a group of peers worth examining would be PHUN, CDZI, MCFE, AUY, and EB.
  • THMO's SEC filings can be seen here. And to visit ThermoGenesis Holdings Inc's official web site, go to www.thermogenesis.com.

THMO Valuation Summary

  • THMO's price/sales ratio is 3.6; this is 5.26% lower than that of the median Healthcare stock.
  • THMO's EV/EBIT ratio has moved up 7.9 over the prior 243 months.
  • THMO's price/sales ratio has moved down 9.2 over the prior 243 months.

Below are key valuation metrics over time for THMO.

Stock Date P/S P/B P/E EV/EBIT
THMO 2021-08-31 3.6 3.6 -2.4 -4.8
THMO 2021-08-30 3.5 3.5 -2.3 -4.6
THMO 2021-08-27 3.5 3.5 -2.3 -4.6
THMO 2021-08-26 3.5 3.5 -2.3 -4.6
THMO 2021-08-25 3.5 3.5 -2.3 -4.6
THMO 2021-08-24 3.4 3.4 -2.2 -4.5

THMO Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 29.19%.
  • Its 5 year net income to common stockholders growth rate is now at 29.19%.
  • The 4 year cash and equivalents growth rate now stands at -7.29%.
Over the past 67 months, THMO's revenue has gone down $3,828,000.

The table below shows THMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 8.823 -8.828 -11.575
2021-06-30 8.02 -10.684 -12.264
2021-03-31 8.061 -15.804 -14.162
2020-12-31 9.744 -14.393 -16.351
2020-09-30 9.519 -11.601 -17.549
2020-06-30 11.222 -9.302 -17.368

THMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • THMO has a Quality Grade of D, ranking ahead of 11.36% of graded US stocks.
  • THMO's asset turnover comes in at 0.381 -- ranking 53rd of 75 Measuring and Control Equipment stocks.
  • COHU, MKSI, and KLAC are the stocks whose asset turnover ratios are most correlated with THMO.

The table below shows THMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.381 0.510 -0.584
2021-03-31 0.398 0.059 -0.764
2020-12-31 0.513 0.129 -0.788
2020-09-30 0.542 0.101 -1.088
2020-06-30 0.636 0.120 -1.093
2020-03-31 0.784 0.446 -0.594

THMO Price Target

For more insight on analysts targets of THMO, see our THMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.00 Average Broker Recommendation 1.5 (Moderate Buy)

THMO Stock Price Chart Interactive Chart >

Price chart for THMO

THMO Price/Volume Stats

Current price $0.83 52-week high $4.45
Prev. close $0.85 52-week low $0.78
Day low $0.78 Volume 62,915
Day high $0.84 Avg. volume 170,374
50-day MA $1.12 Dividend yield N/A
200-day MA $2.00 Market Cap 9.89M

Thermogenesis Holdings, Inc. (THMO) Company Bio


Thermogenesis Holdings, Inc. serves customers in the United States.


THMO Latest News Stream


Event/Time News Detail
Loading, please wait...

THMO Latest Social Stream


Loading social stream, please wait...

View Full THMO Social Stream

Latest THMO News From Around the Web

Below are the latest news stories about ThermoGenesis Holdings Inc that investors may wish to consider to help them evaluate THMO as an investment opportunity.

ThermoGenesis Holdings to Hold Reconvened Annual Meeting of Stockholders on January 13, 2022

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), today announced that the Company's 2021 Annual Meeting of Stockholders (the "Annual Meeting") will reconvene on Thursday, January 13, 2022 at 12:00 p.m. EST. The meeting, originally scheduled for December 16, 2021, was convened and adjourned without any business being conducted due to lack of the required quorum.

Yahoo | January 11, 2022

ThermoGenesis Holdings to Present at the H.C. Wainwright BioConnect Virtual Conference

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Chief Financial Officer, Jeff Cauble, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022.

Yahoo | January 10, 2022

ThermoGenesis Holdings Announces Adjournment of Annual Meeting of Stockholders

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), announced that the Company's Annual Meeting of Stockholders (the "Annual Meeting") scheduled for Thursday, December 16, 2021 at 9:00 a.m. PST, was convened and adjourned without any business being conducted due to lack of the required quorum.

Yahoo | December 17, 2021

Analysts Expect Breakeven For ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Before Long

We feel now is a pretty good time to analyse ThermoGenesis Holdings, Inc.'s ( NASDAQ:THMO ) business as it appears the...

Yahoo | December 6, 2021

ThermoGenesis Holdings Announces Financial Results for the Third Quarter Ended September 30, 2021, and Provides Corporate Update

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the third quarter ended September 30, 2021 and provided a corporate strategic update.

Yahoo | November 12, 2021

Read More 'THMO' Stories Here

THMO Price Returns

1-mo -20.19%
3-mo -46.45%
6-mo -64.07%
1-year -73.57%
3-year -76.94%
5-year -97.20%
YTD -17.82%
2021 -51.67%
2020 -52.50%
2019 64.79%
2018 -91.10%
2017 -13.04%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7819 seconds.